Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars.
Joined January 2019
- Tweets 387
- Following 65
- Followers 320
- Likes 210
211 Photos and videos
Formycon reports positive operational Progress and strong Revenue Growth in the First Quarter of 2026
formycon.com/en/blog/press-rโฆ
1
1
47
Formycon invites to conference call on the results of the first quarter of 2026. The conference call will take place on Thursday, May 28, 2026, at 3:00 PM (CEST) in English: webcast-eqs.com/formycon-202โฆ
2
48
๐
๐จ๐ซ๐ฆ๐ฒ๐๐จ๐งโ๐ฌ ๐๐๐ฅ๐ข๐๐๐ซ๐๐๐ฉ๐ญ ๐๐ข๐จ๐ฌ๐ข๐ฆ๐ข๐ฅ๐๐ซ๐ฌ ๐ฅ๐๐ฎ๐ง๐๐ก๐๐ ๐ข๐ง ๐๐ฎ๐ซ๐จ๐ฉ๐: formycon.com/en/blog/press-rโฆ
1
2
65
For information on the 2025 financial results and the outlook for 2026, please refer to our corporate news: formycon.com/en/blog/press-rโฆ
For full details on the financial results, please refer to the Annual Report on our website: formycon.com/wp-content/uploโฆ
1
36
๐๐จ๐ง๐๐๐ซ๐๐ง๐๐ ๐๐๐ฅ๐ฅ
๐จ๐ง ๐ญ๐ก๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐๐จ๐ซ ๐ญ๐ก๐ ๐๐๐๐ ๐
๐ข๐ฌ๐๐๐ฅ ๐๐๐๐ซ
To follow the conference live, please register via the following link: webcast-eqs.com/formycon-202โฆ
Access the replay at: formycon.com/en/investor-relโฆ
22
The European Biotechnology Science & Industry Guide is more than just a โWho's Whoโ of European biotechnology. It also highlights current developments in innovation, deals and financing. With its biosimilar projects, Formycon is happy to be featured in the current edition.
44
๐
๐จ๐ซ๐ฆ๐ฒ๐๐จ๐ง ๐ฌ๐๐๐ฎ๐ซ๐๐ฌ ๐ฅ๐ข๐๐๐ง๐ฌ๐ ๐๐๐ญ๐ ๐๐จ๐ซ ๐
๐๐๐๐๐ ๐ข๐ง ๐๐ฎ๐ซ๐จ๐ฉ๐ ๐๐ง๐ ๐๐ฎ๐ซ๐ญ๐ก๐๐ซ ๐ญ๐๐ซ๐ซ๐ข๐ญ๐จ๐ซ๐ข๐๐ฌ
Market launches by commercialization partners across Europe to start in May 2026
formycon.com/en/blog/press-rโฆ
63
๐ฌ
Dahlia study demonstrates PK equivalence of FYB206 with the reference drug Keytrudaยฎ
formycon.com/en/blog/press-rโฆ
1
1
74
We are happy to announce another milestone in our global commercialization journey for FYB206:
formycon.com/en/blog/press-rโฆ
4
145
The FDA has approved Nufymcoยฎ, another interchangeable #ranibizumab #biosimilar in the U.S., underscoring Formyconโs pioneering position in high-quality biosimilar #development: formycon.com/en/blog/press-rโฆ
2
96
Zydus Lifesciences Limited to commercialize Formyconโs Keytruda biosimilar FYB206 in the US and Canada: formycon.com/en/blog/press-rโฆ
1
111
Formycon starts commercial partnering activities for #FYB206: MS Pharma will commercialize the Keytrudaยฎ biosimilar candidate in the #MENA region: formycon.com/en/blog/press-rโฆ
2
93
Immunological Dupilumab Biosimilar Candidate FYB208 as another growth driver in Formycon's portfolio
formycon.com/en/blog/press-rโฆ
2
140
#WorldPsoriasisDay
Psoriatic Disease and Comorbidities -
Early Diagnosis and proper Treatment save Lives
formycon.com/en/blog/2025/10โฆ
2
62
Formycon sets a new standard: FYB201/Ranivisioยฎis the first ranibizumab biosimilar on the European market in a pre-filled syringe presentation
For more information, please check our press release at:
formycon.com/en/blog/press-rโฆ
1
2
108
Additional commercialization partnerships for FYB203 to open up further important regions of the world:
formycon.com/en/blog/press-rโฆ
2
101
Preserving vision โ
Anti-VEGF therapies for severe retinopathies
๐๏ธโ On World Sight Day, we we are turning our attention to retinopathies, in other words: diseases of the retina that can be responsible for severe visual impairment and even blindness: formycon.com/en/blog/2025/10โฆ
1
59
Formycon and Klinge expand their European commercialization strategy for the Eyleaยฎ biosimilar FYB203 with Horus Pharma as additional commercialization partner
formycon.com/en/blog/press-rโฆ
2
125
